108 related articles for article (PubMed ID: 16417731)
1. Controlled natural cycle IVF with antagonist use and blastocyst transfer.
Trokoudes KM; Minbattiwalla MB; Kalogirou L; Pantelides K; Mitsingas P; Sokratous A; Chrysanthou A; Fasouliotis SJ
Reprod Biomed Online; 2005 Dec; 11(6):685-9. PubMed ID: 16417731
[TBL] [Abstract][Full Text] [Related]
2. Revival of the natural cycles in in-vitro fertilization with the use of a new gonadotrophin-releasing hormone antagonist (Cetrorelix): a pilot study with minimal stimulation.
Rongières-Bertrand C; Olivennes F; Righini C; Fanchin R; Taïeb J; Hamamah S; Bouchard P; Frydman R
Hum Reprod; 1999 Mar; 14(3):683-8. PubMed ID: 10221695
[TBL] [Abstract][Full Text] [Related]
3. [A prospective, randomized controlled study comparing the effects of gonadotropin-releasing hormone agonist long and short protocols for in vitro fertilization].
Ye H; Huang G; Pei L
Zhonghua Fu Chan Ke Za Zhi; 2001 Apr; 36(4):222-5. PubMed ID: 11783366
[TBL] [Abstract][Full Text] [Related]
4. Precycle administration of GnRH antagonist and microdose HCG decreases clinical pregnancy rates without affecting embryo quality and blastulation.
Bukulmez O; Rehman KS; Langley M; Carr BR; Nackley AC; Doody KM; Doody KJ
Reprod Biomed Online; 2006 Oct; 13(4):465-75. PubMed ID: 17007662
[TBL] [Abstract][Full Text] [Related]
5. Dual trigger with combination of gonadotropin-releasing hormone agonist and human chorionic gonadotropin significantly improves the live-birth rate for normal responders in GnRH-antagonist cycles.
Lin MH; Wu FS; Lee RK; Li SH; Lin SY; Hwu YM
Fertil Steril; 2013 Nov; 100(5):1296-302. PubMed ID: 23993928
[TBL] [Abstract][Full Text] [Related]
6. HCG administration after endogenous LH rise negatively influences pregnancy rate in modified natural cycle for frozen-thawed euploid blastocyst transfer: a pilot study.
Litwicka K; Mencacci C; Arrivi C; Varricchio MT; Caragia A; Minasi MG; Greco E
J Assist Reprod Genet; 2018 Mar; 35(3):449-455. PubMed ID: 29147846
[TBL] [Abstract][Full Text] [Related]
7. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
[TBL] [Abstract][Full Text] [Related]
8. Clinical efficacy of the gonadotropin-releasing hormone antagonist, ganirelix, in Korean women undergoing controlled ovarian hyperstimulation for in vitro fertilization and embryo transfer with recombinant follicle-stimulating hormone.
Moon SY; Ku SY; Kim SM; Jee BC; Suh CS; Choi YM; Kim JG; Kim SH
J Obstet Gynaecol Res; 2005 Jun; 31(3):227-35. PubMed ID: 15916659
[TBL] [Abstract][Full Text] [Related]
9. Intrauterine administration of hCG immediately after oocyte retrieval and the outcome of ICSI: a randomized controlled trial.
Navali N; Gassemzadeh A; Farzadi L; Abdollahi S; Nouri M; Hamdi K; Mallah F; Jalilvand F
Hum Reprod; 2016 Nov; 31(11):2520-2526. PubMed ID: 27680029
[TBL] [Abstract][Full Text] [Related]
10. Low-dose human chorionic gonadotropin may improve in vitro fertilization cycle outcomes in patients with low luteinizing hormone levels after gonadotropin-releasing hormone antagonist administration.
Propst AM; Hill MJ; Bates GW; Palumbo M; Van Horne AK; Retzloff MG
Fertil Steril; 2011 Oct; 96(4):898-904. PubMed ID: 21839437
[TBL] [Abstract][Full Text] [Related]
11. Human recombinant luteinizing hormone is as effective as, but safer than, urinary human chorionic gonadotropin in inducing final follicular maturation and ovulation in in vitro fertilization procedures: results of a multicenter double-blind study.
European Recombinant LH Study Group
J Clin Endocrinol Metab; 2001 Jun; 86(6):2607-18. PubMed ID: 11397861
[TBL] [Abstract][Full Text] [Related]
12. Basal serum progesterone and history of elevated progesterone on the day of hCG administration are significant predictors of late follicular progesterone elevation in GnRH antagonist IVF cycles.
Venetis CA; Kolibianakis EM; Bosdou JK; Lainas GT; Sfontouris IA; Tarlatzis BC; Lainas TG
Hum Reprod; 2016 Aug; 31(8):1859-65. PubMed ID: 27301360
[TBL] [Abstract][Full Text] [Related]
13. Gonadotropin-releasing hormone antagonist versus agonist administration in women undergoing controlled ovarian hyperstimulation: cycle performance and in vitro steroidogenesis of granulosa-lutein cells.
Minaretzis D; Alper MM; Oskowitz SP; Lobel SM; Mortola JF; Pavlou SN
Am J Obstet Gynecol; 1995 May; 172(5):1518-25. PubMed ID: 7755066
[TBL] [Abstract][Full Text] [Related]
14. Reproductive outcomes after a single dose of gonadotropin-releasing hormone agonist compared with human chorionic gonadotropin for the induction of final oocyte maturation in hyper-responder women aged 35-40 years.
Tannus S; Turki R; Cohen Y; Son WY; Shavit T; Dahan MH
Fertil Steril; 2017 Jun; 107(6):1323-1328.e2. PubMed ID: 28501366
[TBL] [Abstract][Full Text] [Related]
15. A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). The ganirelix dose-finding study group.
Hum Reprod; 1998 Nov; 13(11):3023-31. PubMed ID: 9853849
[TBL] [Abstract][Full Text] [Related]
16. Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles.
Toftager M; Bogstad J; Bryndorf T; Løssl K; Roskær J; Holland T; Prætorius L; Zedeler A; Nilas L; Pinborg A
Hum Reprod; 2016 Jun; 31(6):1253-64. PubMed ID: 27060174
[TBL] [Abstract][Full Text] [Related]
17. Dual suppression with oral contraceptives and gonadotrophin releasing-hormone agonists improves in-vitro fertilization outcome in high responder patients.
Damario MA; Barmat L; Liu HC; Davis OK; Rosenwaks Z
Hum Reprod; 1997 Nov; 12(11):2359-65. PubMed ID: 9436663
[TBL] [Abstract][Full Text] [Related]
18. A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol.
Hohmann FP; Macklon NS; Fauser BC
J Clin Endocrinol Metab; 2003 Jan; 88(1):166-73. PubMed ID: 12519847
[TBL] [Abstract][Full Text] [Related]
19. Luteinizing hormone concentrations after gonadotropin-releasing hormone antagonist administration do not influence pregnancy rates in in vitro fertilization-embryo transfer.
Merviel P; Antoine JM; Mathieu E; Millot F; Mandelbaum J; Uzan S
Fertil Steril; 2004 Jul; 82(1):119-25. PubMed ID: 15236999
[TBL] [Abstract][Full Text] [Related]
20. 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study.
Humaidan P; Ejdrup Bredkjaer H; Westergaard LG; Yding Andersen C
Fertil Steril; 2010 Feb; 93(3):847-54. PubMed ID: 19200959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]